AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.28) by 71.43 percent. This is a 91.49 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $117.00 thousand which missed the analyst consensus estimate of $130.00 thousand by 10.00 percent. This is a 76.92 percent decrease over sales of $507.00 thousand the same period last year.